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Abstract
Background: Lower respiratory tract infections are a major cause of illness and death. Such
infections are common in intensive care units (ICU) and their lethality persists despite advances in
diagnosis, treatment and prevention. In Mexico, some plants are used in traditional medicine to
treat respiratory diseases or ailments such as cough, bronchitis, tuberculosis and other infections.
Medical knowledge derived from traditional societies has motivated searches for new bioactive
molecules derived from plants that show potent activity against bacterial pathogens. Therefore, the
aim of this study was to evaluate the effect of hexanic, chloroformic (CLO), methanolic (MET) and
aqueous extracts from various plants used in Mexican traditional medicine on various
microorganisms associated with respiratory disease.
Methods: thirty-five extracts prepared from nine plants used in Mexican traditional medicine for
the treatment of respiratory infections were evaluated against 15 control bacterial species and
clinical isolates.
Results: Both chloroformic (CLO) and methanolic (MET) extracts of Larrea tridentata were active
against Methicillin-resistant S. aureus, B. subtilis and L. monocytogenes. A MET extract of L. tridentata
was also active against S. aureus, S. pneumoniae, S. maltophilia, E. faecalis and H. influenzae and the
CLO extract was active against A. baumannii. An Aqueous extract of M. acumitata and a MET extract
of N. officinale were active against S. pneumoniae. CLO and MET extracts of L. tridentata were active
against clinical isolates of S. aureus, S. pneumoniae and E. faecalis.
Conclusion: Overall, our results support the potential use of L. tridentata as a source of
antibacterial compounds.
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Lower respiratory tract infections are a major cause of ill-
ness and death and are common in intensive care units
(ICU) [1,2]. The most frequent causal agents of these
infections are Streptococcus pneumoniae, Klebsiella pneumo-
niae, Staphylococcus aureus, Haemophilus influenzae, Pseu-
domonas aeruginosa, Acinetobacter baumannii and
Stenotrophomonas maltophilia. Some additional and less
frequent causative agents are Escherichia coli, Enterobacter
cloacae, Bacillus subtilis [3], Bacillus cereus [4], Listeria mono-
cytogenes [5], and Enterococcus faecalis [6].
Infections with these bacteria are associated with high
morbidity and mortality, especially in immunocompro-
mised patients [7-10]. Methicillin-resistant S. aureus
(MRSA) is of particular concern in the United States since
approximately 60% of all staphylococcal infections in the
ICU are caused by MRSA [11,12]. Penicillin-resistant S.
pneumoniae and vancomycin-resistant enterococci are an
additional cause for concern in the clinical setting [13].
In Mexico, some plants are used in traditional medicine to
treat respiratory diseases or ailments such as cough, bron-
chitis, tuberculosis and other infections [14,15]. The
known success of these traditional therapies has guided
the search for new chemotherapeutic alternatives to fight
respiratory and other infections caused by drug-resistant
bacteria [16-18]. Therefore, the aim of this study was to
evaluate the effect of hexanic, chloroformic (CLO), meth-
anolic (MET) and aqueous extracts from various plants
used in Mexican traditional medicine on various microor-
ganisms associated with respiratory disease.
Plant material and preparation of extracts
We reviewed Mexican ethnobotanical literature and
selected a group of plants used by traditional healers to
treat respiratory infections [14,15]. In 2004, nine plants
were collected by the biologist Mauricio Gonzalez-Ferrara
from different states of Mexico, and authenticated by the
Biologist Marcela González-Alvarez. Voucher specimens
were deposited at the UANL herbarium located in the Fac-
ultad de Ciencias Biológicas of the Universidad Auton-
oma de Nuevo Leon, Mexico.
Plant names, author of the name, plant family, parts used,
voucher number, and the state where collected were as fol-
lows: Citrus aurantifolia (Christm) Swingle (Rutaceae),
fruit peel, 024769, Nuevo Leon; Citrus sinensis (L) Osbeck
(Rutaceae), fruit peel, 024770, Nuevo Leon; Foeniculum
vulgare P. Mill (Umbelliferae), aerial parts, 024771, Chi-
huahua; Larrea tridentata (Sessé & Moc. ex. DC) Coville
(Zygophyllaceae), aerial parts, 024772, Nuevo Leon;
Nasturtium officinale R. Br. (Cruciferae), aerial parts,
024774, Nuevo Leon; Olea europaea L (Oleaceae), leaves,
024775, Nuevo Leon; Mentha pulegium L. (Labiatae),
leaves, 024777, purchased in the Sonora Market in Mex-
ico City; Rosa centifolia L. (Rosaceae), petals, 024776,
Morelos and Musa acuminata Colla (Musaceae), stems,
024773, Guerrero.
Approximately 50 g of dried and ground plant material
was successively extracted by maceration with hexane,
chloroform, methanol and water. Organic extracts were
concentrated in vacuo to dryness, and aqueous extracts
were freeze-dried. All extracts were stored at 4°C until use.
Hexanic, CLO, MET and aqueous extracts were made from
the following: C. aurantifolia, C. sinensis, F. vulgare, L. tri-
dentata, N. officinale, O. europaea, M. pulegium, R. centifolia.
Only CLO, MET and aqueous extracts were prepared form
M. acuminata because of limited plant material availabil-
ity.
Stock solutions were prepared from extracts at a concen-
tration of 20 mg/ml. For organic extracts, DMSO was used
as a solvent. Aqueous extracts were prepared in distilled
water and sterilized by filtration through a 0.22 μm mem-
brane.
Bacterial strains and preparation of inocula
Two sets of control species or phenotypic groups of bacte-
ria were tested. The Gram-negative bacteria were S. mal-
tophilia ATCC 12714, E. coli ATCC 25922, A. baumannii
ATCC 15308, H. influenzae ATCC 49766, H. influenzae
ATCC 49247, P. aeruginosa ATCC 27853, K. pneumoniae
ATCC 700603 and E. cloacae ATCC 35030. The Gram-pos-
itive strains were: S. aureus ATCC 29213, S. aureus MRSA
ATCC BAA-44, B. subtilis ATCC 6633, B. cereus ATCC
49064, S. pneumoniae ATCC 49619, L. monocytogenes
ATCC 19111 and E. faecalis ATCC 29212.
Before testing, strains were inoculated onto plates pre-
pared with 5% blood agar and cultured overnight at 37°C.
For H. influenzae, strains were inoculated onto chocolate
agar and incubated in a 5% CO2 atmosphere for 48 h. Tur-
bidity was adjusted to 0.5 of the McFarland standard to
prepare the test inoculum. Afterwards, 10 μl were trans-
ferred into 11 ml Mueller Hinton broth to achieve 5 × 105
CFU/ml. HTM medium was used for H. influenzae and
Mueller Hinton with TES/lysed horse blood was used for
S. pneumoniae.
Screening of antimicrobial activity and reference drugs
Minimal inhibitory concentration (MIC) for each extract
was determined for both Gram-negative and Gram-posi-
tive bacteria by the microdilution method [19] with dilu-
tions ranging from 250 to 7.8 μg/ml. Extracts that caused
complete inhibition of growth at 24 h were considered
active and used for the subsequent assays. All assays were
performed in duplicate.Page 2 of 5
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further tested against clinical isolates of susceptible spe-
cies collected at the Hospital Universitario "Dr. José Eleu-
terio" Gonzalez and deposited at the Microbiology
Department, School of Medicine, UANL. These isolates
included A. baumannii (n = 25), E. faecalis (n = 15), S.
aureus (n = 25), and S. pneumoniae (n = 13; total n = 78).
H. influenzae was not included because clinical isolates
were not available.
For all assays, adequate media without drug or extract was
used as control.
As a reference for the screening assays, MICs for the anti-
microbial drugs ceftazidime (Caz), ciprofloxacin, levo-
floxacin (Lv) and vancomycin (Va) were determined by
the broth microdilution method recommended by the
Clinical and Laboratory Standards Institute [20]. As a ref-
erence for the assays with clinical isolates, we evaluated
the susceptibility pattern for each clinical isolate against
the following commonly used antibiotics: Caz, Lv, Va,
minocycline, penicillin, piperacillin tazobactam, amoxi-
cillin clavulanic acid, ampicillin, linezolid, meropenem,
amikacin, cefepime, and/or ceftriaxone.
Results
CLO and MET extracts of L. tridentata, MET extract of N.
officinale and aqueous extract of M. acuminata were all
active against several Gram-positive bacteria and Gram-
negative bacteria [see Additional file 1]. None of the 35
extracts were active against B. cereus, E. coli, P. aeruginosa,
K. pneumoniae or E. cloacae strains at the tested concentra-
tions. Hexanic, CLO, MET and aqueous extracts of C.
aurantiifolia, C. sinensis, F. vulgare, M. pulegium, O. europaea
and R. centifolia did not show activity against any of the 15
bacteria of phenotypic groups.
We selected the CLO and MET extracts of L. tridentata
because of their broad bioactivity and evaluated their
effects on clinical isolates of species that showed sensitiv-
ity to these extracts. The clinical isolates included were A.
baumannii (n = 25), E. faecalis (n = 15), S. pneumoniae (n
= 13) and S. aureus (n = 25). The most potent antibacterial
activity occurred against the S. pneumoniae strains [see
Additional file 2] with MIC50 and MIC80 values of 31.25μg/ml for both CLO and MET extracts, respectively. These
extracts also showed potent activity against E. faecalis (n =
15, MIC50 = 250 μg/ml for both extracts) and S. aureus (n
= 25, MIC80 = 125 μg/ml for both extracts) [see Additional
file 2]. No activity was detected against any clinical iso-
lates of A. baumannii (n = 25).
Discussion and conclusion
Among the plant extracts that showed antibacterial activ-
ity, the CLO and MET extracts of L. tridentata showed the
broadest and most promising spectrum of activity. In
order to confirm this activity, we tested those extracts
against clinical isolates of species that showed sensitivity
to these extracts in the screening assay.
Both extracts confirmed the antibacterial activity, not only
in control strains, but also against strains isolated from
patient's clinical samples. The best activity was observed
against S. pneumoniae (MICs80 = 31.25 μg/ml). When
tested against S. pneumoniae, the antimicrobial activity of
CLO and MET extracts of L. tridentata were comparable to
the activity observed for reference antimicrobial drugs. It
is possible that further isolation of the active com-
pound(s) will render lower MIC values.
Both the CLO and MET extracts of L. tridentata also
showed good activity against E. faecalis (MICs50 = 250 μg/
ml) and S. aureus (MICs80= 125 μg/ml). These results are
quite interesting, given the high drug-resistance observed
for those clinical isolates. The CLO and MET extracts of L.
tridentata were active against MDR clones of S. aureus.
These results are particularly important because of the
increase in morbidity and mortality related to clones of
MDR S. aureus in the last two decades [11].
No activity was detected against any clinical isolates of A.
baumannii. Nevertheless, this is not a surprising result sin-
ceclinical isolates of A. baumannii show a strong drug-
resistance, so there are likely multiple antimicrobial-
resistance mechanisms in these strains.
The CLO and MET extracts of L. tridentata showed differ-
ent activity spectra. Verastegui et al. reported that eth-
anolic extract of L. tridentata was active against L.
monocytogenes, Clostridium perfringens, Shigella dysenteriae,
Yersinia enterocolitica and Proteus vulgaris, with a MIC rang-
ing from 10 to 19 μg/ml, yet they did not find activity
against E. coli [21]. We found that CLO and MET extracts
of L. tridentata showed activity against L. monocytogenes
and no activity against E. coli. This confirms the antibiotic
activity of L. tridentata extracts; however, it is difficult to
compare our results directly with Verastegui et al. because
we did not include these ethanolic extracts in our study.
L. tridentata (Creosote bush) is an abundant plant of Mex-
ican and US-American deserts. The potent antioxidant
nordihydroguaiaretic acid (NDGA) has been identified
from this plant [22]. This lignan is a potential therapeutic
molecule for Sjorgren-Larsson syndrome, cardiopathies,
skin cancer prevention, and viral infections [23]. We pre-
sume that the compounds present in our L. tridentata CLO
extract are not NDGA because they have a different polar-
ity. Thus, they are potentially novel antibacterial mole-
cules. Antimicrobial properties for some plant species
tested in the study have previously been described but notPage 3 of 5
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inclusion of some bacterial MDR clones.
Our results showed that the MET extract of N. officinale
and the aqueous extract of M. acuminata were active
against S. pneumoniae. N. officinale has been used for the
treatment of renal, liver disease [24], and has also been
shown to reduce oxidative stress in hypercholesterolemic
rats [25]. This plant has also been shown to have cardio-
protective activity [26] and antimycobacterial potential
[27]. Indeed, several antimicrobial compounds have been
identified in N. officinale. Specifically, a phenyl-phenal-
enone has been isolated and evaluated for leishmanicidal
activity and isolated phytoalexins are known to have anti-
fungal activity [28]. We found that the methanolic extract
of N. officinale is active against S. pneumoniae.
Our results also demonstrated the activity of M. acuminata
aqueous extract against S. pneumoniae ATCC 49619 (250
μg/ml). Similarly, activity of M. acuminata MET extract
against Mycobacterium tuberculosis has been previously
reported [27]. To our knowledge, there is no other antimi-
crobial activity report for extracts form M acuminata.
Our findings do conflict with some of the previously pub-
lished results on the same plant extracts. We did not find
antibacterial activity in several plants whose antimicrobial
effects have been documented. For example, we did not
find any antibacterial activity in extract from O. europaea,
yet another group isolated the aldehyde hexanal extract
from O. europaea and reported bioactivity against multiple
types of microorganisms [29]. In addition, a terpenoid
extracted from C. sinensis with antifungal activity has been
isolated from the fruit peel [30], yet we found no effect of
the extract in our study.
The differences between our study and theirs could have
multiple explanations. The strains or clones and the test-
ing concentrations differed and perhaps local environ-
mental factors that affect the potency of medicinal plants,
such as temperature, rainfall, day length and soil charac-
teristics may have differed between the plant samples used
for each study. Also, it is important to consider differences
in the conditions of extract preparation and in the extract
concentrations tested.
Our study has provided and confirmed previous evidence
that L. tridentata is a promising alternative source for anti-
microbial compounds. It is particularly valuable in the
context of the bacterial resistance that is prevalent. Our
group is currently conducting a study to isolate the active
compounds in this extract.
Lastly, the activity observed for L. tridentata provides a
rationale for its use in the treatment of respiratory infec-
tious diseases in traditional medicine.
List of abbreviations
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